Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management

Padma Raghavan Pillai1, Mindy Griffith, Monica D Schwarcz

  • 1From the Division of Endocrinology, Department of Medicine, Westchester Medical Center at New York Medical College, Valhalla, NY.

Cardiology in Review
|December 24, 2019
PubMed

Insights

Primary aldosteronism is a common cause of secondary hypertension, posing diagnostic and management challenges. This review covers diagnosis, cardiovascular effects, and treatment options like medication and surgery, emphasizing a collaborative approach.

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Primary aldosteronism is a significant cause of secondary hypertension.
  • Diagnosis and management present ongoing clinical challenges.
  • Cardiovascular manifestations are a key concern.

Purpose of the Study:

  • To review the diagnostic approaches for primary aldosteronism.
  • To discuss the cardiovascular implications of the condition.
  • To outline current treatment strategies.

Main Methods:

  • Review of existing literature on primary aldosteronism.
  • Analysis of diagnostic algorithms and testing complexities.
  • Examination of treatment modalities including medical and surgical options.

Main Results:

  • Screening and diagnosis can be complex, particularly in confirming laterality.
  • Mineralocorticoid receptor antagonists and unilateral adrenalectomy are primary treatments.
  • A multidisciplinary approach is essential for effective patient care.

Conclusions:

  • Accurate diagnosis and management of primary aldosteronism require a comprehensive understanding of its complexities.
  • Effective treatment necessitates collaboration among various medical specialists.
  • Addressing primary aldosteronism is crucial for managing secondary hypertension and its cardiovascular sequelae.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
326
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
284
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
400
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K